Abstract Background The role of GI microbiome in gut health, intestinal permeability, and the development of inflammation has been well-established however, few clinical studies assess microbiome (i.e. PCR) and biochemical markers from the same stool collection. Doctor’s Data Inc. (DDI) has been performing a GI microbiome test in conjunction with other stool biochemical markers for the past 3 years, with over 7000 patient samples analyzed. The aim of this study was to analyze GA-map® Probe results for possible correlations with elevated values for fecal calprotectin, lactoferrin, and lysozyme. Methods Microbiome characterization The microbiome analysis test used in this study identifies 48 targeted analytes across six phyla using the GA-map® Dysbiosis test (Genetic Analysis AS, Oslo). The test algorithm has been trained and validated using 48 bacterial markers signal intensity obtained from 668 adults, including healthy subjects, patients with IBS and IBD. GA-map® Dysbiosis Analyzer software calculates the degree of dysbiosis (DI) of a given sample, assigning a DI ranging from 1 to 5. DI greater than 2 indicates that the microbiota is deviant from a healthy reference population (“dysbiotic”), while a score of 2 or lower is reported as “normobiotic”. Biochemical marker characterization Each stool sample was analyzed for a suite of biochemical markers - in particular calprotectin, lactoferrin and lysozyme - with the concentration determined using commercially available ELISA kits (ALPCO, Techlab). Results Using clinical cut-offs of 100.0 ug/g (calprotectin) and 7.3 ug/g (lactoferrin) the patient data was sorted into cohorts indicating disease state of “Normal”, “Intermediate” and “IBD Likely”, and further differentiated using the lysozyme result. The biochemical marker results were correlated against DI score for each stool sample (Figure 1). Conclusions DI score increases as biochemical inflammatory markers increase, with lysozyme as the key differentiating factor between patient cohorts.